Xiantong Pharmaceutical
Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases, and cardiovascular diseases. The company has developed nuclear medicine for the treatment. It has also developed several diagnostic agents. Founded in 2004, headquartered in Beijing, China. The company has raised $99.5M in funding at the series e stage. The team comprises 10 (Jun 30, 2026) employees. The company operates in…
Funding snapshot
About
Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases, and cardiovascular diseases. The company has developed nuclear medicine for the treatment. It has also developed several diagnostic agents. Founded in 2004, headquartered in Beijing, China. The company has raised $99.5M in funding at the series e stage. The team comprises 10 (Jun 30, 2026) employees. The company operates in the Oncology sector with additional focus on Genomics. Its business model centers on Diversified. Founded in 2004, headquartered in Beijing, China. The company has raised $99.5M at the Series E stage. Backed by investors including SDIC, Goldstone Investment, National Research Fund, General Technology Venture Capital, CITIC and others.
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Theranostics
Institutional investors
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.
Raising like Xiantong Pharmaceutical?
Analyze your pitch deck before your next raise.
Analyze My Deck →